CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed" or the "Company"), a late-stage clinical pharmaceutical company dedicated to the discovery, development and
Paul Sekhri is a life science executive with more than 35 years of experience building and leading companies from early development through commercializationAppointment comes as iOnctura prepares for late-stage
CAMBRIDGE, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel
CAMBRIDGE, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed" or the "Company"), a late-stage clinical pharmaceutical company dedicated to the discovery, development and
U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi™, and assigned a PDUFA target action date of February 28, 2027 If approved, Oxnimbi has the
CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed" or the "Company"), a late stage clinical pharmaceutical company dedicated to the discovery, development and
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (NASDAQ:APMD) ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel
CAMBRIDGE, Mass., July 30, 2026 /PRNewswire/ -- Apnimed, Inc. ("Apnimed"), a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that
